Micromet To Participate in the 2010 RBC Capital Markets Healthcare Conference
BETHESDA, Md., Feb. 25 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that the Company will participate in the 2010 RBC Capital Markets Healthcare Conference, to be held March 2 - 3, 2010 in New York City. áChristian Itin, Ph.D., the Company's President and CEO, will participate in a panel discussion titled New Targets in Cancer Therapy on March 2, 2010 at 8:00 AM ET.
The panel discussion will be webcast live and may be accessed at: http://www.wsw.com/webcast/rbc116/panel1/. A replay of the webcast will also be available on the Company's website at www.micromet-inc.com.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE« technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
SOURCE Micromet, Inc.